NRx Pharmaceuticals, Inc. (NRXP)

NASDAQ: NRXP · IEX Real-Time Price · USD
0.472
-0.058 (-10.96%)
At close: Mar 28, 2024, 4:00 PM
0.490
+0.018 (3.84%)
After-hours: Mar 28, 2024, 5:05 PM EDT
-10.96%
Market Cap 48.99M
Revenue (ttm) n/a
Net Income (ttm) -36.06M
Shares Out 92.43M
EPS (ttm) -0.50
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,534,131
Open 0.480
Previous Close 0.530
Day's Range 0.416 - 0.540
52-Week Range 0.221 - 1.200
Beta 0.99
Analysts Strong Buy
Price Target 2.00 (+323.82%)
Earnings Date Mar 28, 2024

About NRXP

NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics based on N-methyl-D-aspartate platform for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned FDA-designated investigational breakthrough therapy for suicidal treatment-resistant bipolar depression and chronic pain; and NRX-100 (ketamin... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Employees 2
Stock Exchange NASDAQ
Ticker Symbol NRXP
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for NRXP stock is "Strong Buy" and the 12-month stock price forecast is $2.0.

Price Target
$2.0
(323.82% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

NRx Pharmaceuticals (NASDAQ:NRXP) Reports Preliminary Fourth Quarter and Full Year 2023 Financial Results and Provides Year End Highlights

Four potential near-term milestones, including data from two clinical trials, an NDA filing and a share dividend RADNOR, Pa. , March 28, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (...

9 hours ago - PRNewsWire

NRx Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing

Common Stock Will Begin Trading on Split-Adjusted Basis on April 2, 2024 RADNOR, Pa. , March 28, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a...

9 hours ago - PRNewsWire

UPDATE: NRx Pharmaceuticals (NASDAQ: NRXP) to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024

RADNOR, Pa., March 26, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will re...

2 days ago - PRNewsWire

NRx Pharmaceutical's (NASDAQ:NRXP) Chairman Dr. Jonathan Javitt to Present at the Ketamine 2024 Conference in Oxford, UK

RADNOR, Pa. , March 25, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that Dr. Jonath...

3 days ago - PRNewsWire

NRx Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Corporate Update on March 28, 2024

RADNOR, Pa., March 21, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will re...

7 days ago - PRNewsWire

NRx Pharmaceuticals Announces Results of the Vote Held During the Special Meeting of Shareholders

61.4% (56,781,354) of eligible shares voted 94.4% of votes were cast in favor of the resolution RADNOR, Pa. , March 21, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceutic...

7 days ago - PRNewsWire

NRx Pharmaceuticals (NASDAQ:NRXP) Announces Plan to Distribute Shares of HOPE Therapeutics and Royalty Rights on Ketamine Sales to Existing NRx Shareholders

NRx Pharmaceuticals Board of Directors has authorized its Chairman, CEO, and management to take all necessary steps to affect the Dividend and Royalty Rights to NRXP Shareholders and applicable warran...

10 days ago - PRNewsWire

NRx Pharmaceuticals (NASDAQ:NRXP) Initiates Strategy to Combat Short Sales

Initiative is intended to protect shareholder value through continued compliance with Nasdaq listing rules and elimination of naked short sales positions in the Company's securities The Company is con...

16 days ago - PRNewsWire

NRx Pharmaceuticals (NASDAQ:NRXP) Completes Memorandum of Understanding and Collaborations with Distribution Partners for HTX-100 (IV Ketamine)

Company to receive first allocation of ketamine for sale by month end Partners preparing to ship IV Ketamine to full range of customers via 503a and 503b pharmacies NRx Pharmaceuticals and HOPE Therap...

17 days ago - PRNewsWire

NRx Pharmaceuticals (NASDAQ: NRXP) Announces Last Patient, Last Visit in its Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression

Marks a major step in the development of what could be the first drug approved for Suicidal Bipolar Depression The study database is being cleaned and locked; statistical analysis and top-line data to...

24 days ago - PRNewsWire

NRx Pharmaceuticals Announces Definitive Purchase Agreement for Common, Unregistered Shares at $0.38 per Share

NRx Pharmaceuticals received approximately $1.0 million in cash from an existing investor Shares were sold at $0.38, a 26.7% premium the recent share offering, along with one common 5-year warrant ($0...

27 days ago - PRNewsWire

NRx Pharmaceuticals, Inc. Announces Pricing of $1.5 Million Underwritten Public Offering of Common Stock Together with investor Commitment for Additional $1 million

RADNOR, Pa. , Feb. 27, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), ("NRx Pharmaceuticals" or the "Company"),  a clinical-stage biopharmaceutical company, today announced the pricing...

4 weeks ago - PRNewsWire

NRx Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Common Stock

RADNOR, Pa. , Feb. 26, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), ("NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, today announced that it inte...

4 weeks ago - PRNewsWire

NRx Pharmaceuticals (Nasdaq:NRXP) Launches HOPE Therapeutics, Inc. at the BIO CEO & Investor Conference 2024

Presentation available on NRx Pharmaceuticals website at https://www.nrxpharma.com/hope-therapeutics/ KEY UPDATES ARE AS FOLLOWS: NRx management is proposing to award 50% of founding shares in HOPE Th...

4 weeks ago - PRNewsWire

NRx Pharmaceuticals (Nasdaq:NRXP) to Launch HOPE Therapeutics, Inc. at the BIO CEO & Investor Conference 2024

HOPE shares currently owned by NRXP with planned share dividend to existing NRXP shareholders HOPE has now completed initial manufacture of Ketamine for IV infusion and plans to file FDA New Drug Appl...

5 weeks ago - PRNewsWire

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces Advance of $5 Million Milestone Payment from Partners Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd. (1975.TW)

Companies continue to work collaboratively to advance NRX-101 through registrational trials NRx remains eligible for an additional $324 million in development and sales milestones, as well as tiered d...

6 weeks ago - PRNewsWire

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Reports Comments by Strategic Partner Lotus Pharmaceutical Co. Ltd. (1975.TW) in Recent Financial Report

Companies continue to work collaboratively to advance NRX-101 in bipolar depression with suicidality Lotus notes that NRx has "achieved a significant milestone by completing enrollment for its phase 2...

6 weeks ago - PRNewsWire

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces the Incorporation of HOPE Therapeutics, Inc., and Planned Share Dividend/Royalty Coupon

HOPE Therapeutics is dedicated to bringing NRX-100 (IV Ketamine) for Suicidal Depression to patients Company to be initially owned by NRx and current NRx shareholders via a planned tax-free dividend A...

7 weeks ago - PRNewsWire

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces Completion of Enrollment of its Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression

Exceeded originally target enrollment (70) with n=74                        Last patient, last visit expected in approximately six weeks; data to follow shortly thereafter Positive data triggers miles...

2 months ago - PRNewsWire

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces Receipt of Positive Nasdaq Listing Determination

RADNOR, Pa. , Jan. 17, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx" or the "Company"), a clinical-stage biopharmaceutical company developing therapies for suicidal depression, ...

2 months ago - PRNewsWire

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation of NRX-101 in Complicated Urinary Tract Infection and Pyelonephritis

NRX-101 has demonstrated potent activity against resistant urinary pathogens upon FDA review QIDP designation grants Priority Review and an additional 5 years of additional product exclusivity 3 milli...

2 months ago - PRNewsWire

NRx Pharmaceuticals (Nasdaq: NRXP) to Present Keynote Address on Ketamine Efficacy and Risks at Upcoming Sachs Neuroscience Innovation Forum in San Francisco

The benefits of ketamine are clear, but so are the risks Ketamine has now demonstrated clear superiority to placebo and non-inferiority to electroshock therapy in randomized trials encompassing more t...

3 months ago - PRNewsWire

NRx Pharmaceuticals (Nasdaq: NRXP) Demonstrates Compliance with Nasdaq MVLS Standard

Company to present full compliance plan, based on achieving clinical milestones, to Nasdaq on January 4, 2024 RADNOR, Pa., Jan. 2, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx P...

3 months ago - PRNewsWire

NRx Pharmaceuticals Announces the Election of Janet Rehnquist to its Board of Directors

Former Inspector General, US Dept. of Health and Human Services Former Assistant US Attorney for the Eastern District of Virginia Nationally recognized attorney in highly regulated industries; healthc...

3 months ago - PRNewsWire

NRx Pharmaceuticals Announces Signing of a Data and Technical Information Agreement with Columbia University Accessing Key Data Demonstrating Efficacy and Safety of Intravenous Ketamine for the Treatment of Suicidal Depression

Ketamine, an NMDA blocker, was highly effective compared to active comparator in rapidly reducing Suicidality (p=0.0003) This study represents the second well-controlled trial NRx has licensed support...

3 months ago - PRNewsWire